Status:
COMPLETED
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
Lead Sponsor:
Genentech, Inc.
Conditions:
Solid Cancers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I, first-in-human, open-label, dose-escalation study of MEGF0444A administered by IV infusion to patients with advanced solid tumors for whom standard therapy either does not exist or ...
Eligibility Criteria
Inclusion
- Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on, or failed to respond to regimens or therapies known to provide clinical benefit
Exclusion
- Inadequate hematologic and organ function
- Anti-cancer therapy within 4 weeks prior to initiation of study treatment
- Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia
- Active infection or autoimmune disease
- Pregnancy (positive pregnancy test) or lactation
Key Trial Info
Start Date :
May 22 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00909740
Start Date
May 22 2009
End Date
October 26 2011
Last Update
December 12 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.